Skip to content

Author

J. Bellmunt

We have 2 of 35 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

A tumor-cell MHC-II program is associated with checkpoint-blockade outcomes across stages of bladder cancer

Purpose A minority of patients with bladder cancer derive lasting benefit from immunotherapy, and current biomarkers capture only part of the biology. We evaluated whether tumor-cell MHC class II defines an immune state associated with outcome across disease stages and after PD-1/PD-L1 blockade. Experimental Design We...

J. Bellmunt, Ying-Tian Xie, M. Munoz et al. · 0 citations
Review Open access Sep 2026

Somatic likelihood tiering: an interpretable post-calling triage protocol for tumor-only whole-exome variant review

SLT provides an auditable tumor-only WES review queue, not a substitute for matched-normal sequencing, independent orthogonal validation, or definitive somatic classification, and is the primary calibration frame.

Konrad Stawiski, S. Kamran, J. Perera-Bel et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.